The present invention includes pourable, non-toxic lubricating compositions containing carrageenan and more precisely λ carrageenan as an anti-viral agent, for protection from Human Papillomavirus (HPV), and methods of using the lubricating compositions as a non-oily, pseudoplastic lubrication product and administering the carrageenan for reducing the propagation of HPV during sexual activity.

A pourable, non-toxic lubricating composition containing lambda carrageenan as an antiviral agent, for protection from viruses, including but not limited to sexually-transmitted viruses and respiratory viruses, and methods of using the lubricating compositions as a non-oily, pseudoplastic lubrication product and administering the carrageenan for reducing the propagation of sexually-transmitted viruses, including HPV, during sexual activity.

The present invention relates to the field of viral infection therapeutic treatments and prophylactic treatments. In particular, provided are methods of treating or preventing viral infections, such as viral infections resulting from entering or infecting a subject via association with or binding to an ACE2 receptor in the subject, with ophthalmic composition, inhalation compositions, and/or topical compositions. In particular, provided are methods of treating or preventing viral infections, such as coronavirus infections, for example COVID-19 infections, in a subject exposed to, or prior to exposure to a coronavirus, for example a COVID-19, by administering an ophthalmic composition, an inhalation composition, and/or a topical composition.

The present invention relates to the field of viral infection therapeutic treatments and prophylactic treatments. In particular, provided are methods of treating or preventing viral infections, such as viral infections resulting from entering or infecting a subject via association with or binding to an ACE2 receptor in the subject, with ophthalmic composition, inhalation compositions, and/or topical compositions. In particular, provided are methods of treating or preventing viral infections, such as coronavirus infections, for example COVID-19 infections, in a subject exposed to, or prior to exposure to a coronavirus, for example a COVID-19, by administering an ophthalmic composition, an inhalation composition, and/or a topical composition.

A pourable, non-toxic lubricating composition containing lambda carrageenan as an antiviral agent, for protection from viruses, including but not limited to sexually-transmitted viruses and respiratory viruses, and methods of using the lubricating compositions as a non-oily, psuedoplastic lubrication product and administering the carrageenan for reducing the propagation of sexually-transmitted viruses, including HPV, during sexual activity.

Disclosed is a water-insoluble polymeric iron chelating agent having a polymer backbone and an aromatic ring attached to the polymer backbone through an —NH—CH.sub.2— bond, wherein the aromatic ring has one or two first functional groups in the form of hydroxyl group and one or two second functional groups located at the ortho position with respect to the first functional group; and wherein the second functional group is —OH, —COOH, or a group represented by formula (I) wherein A represents —CH.sub.3, —CH.sub.2—CH.sub.3, —CH.sub.2—C.sub.6H.sub.5, —CH.sub.2—C.sub.5H.sub.4N or —CH.sub.2—COOH and B represents —CH.sub.2—COOH. The water-insoluble polymeric iron chelating agent of the present invention offers the advantages of being capable of selectively chelating iron ions, particularly biologically unstable iron, and being insoluble in water, and moreover not being incorporated in metabolic processes in vivo.

Disclosed is a water-insoluble polymeric iron chelating agent having a polymer backbone and an aromatic ring attached to the polymer backbone through an —NH—CH.sub.2— bond, wherein the aromatic ring has one or two first functional groups in the form of hydroxyl group and one or two second functional groups located at the ortho position with respect to the first functional group; and wherein the second functional group is —OH, —COOH, or a group represented by formula (I) wherein A represents —CH.sub.3, —CH.sub.2—CH.sub.3, —CH.sub.2—C.sub.6H.sub.5, —CH.sub.2—C.sub.5H.sub.4N or —CH.sub.2—COOH and B represents —CH.sub.2—COOH. The water-insoluble polymeric iron chelating agent of the present invention offers the advantages of being capable of selectively chelating iron ions, particularly biologically unstable iron, and being insoluble in water, and moreover not being incorporated in metabolic processes in vivo.

The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.